Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MVI 118

Next Previous
Drug Profile

MVI 118

Alternative Names: AR vaccine - Madison Vaccines; pTVG-AR

Latest Information Update: 25 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Madison Vaccines
  • Developer Madison Vaccines; University of Wisconsin-Madison
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
  • Mechanism of Action Androgen receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 01 Nov 2021 Phase-I/II clinical trials in Prostate cancer (Adjunctive treatment, Newly diagnosed, Combination therapy) in USA (Intradermal) in November 2021 (NCT04989946)
  • 01 Nov 2021 Phase-I/II clinical trials in Prostate cancer (Newly diagnosed, Adjunctive treatment, Monotherapy) in USA (Intradermal) in November 2021 (NCT04989946)
  • 04 Aug 2021 Madison Vaccines and University of Wisconsin-Madison plans a phase I/II trial for Prostate Cancer (Monotherapy, Newly diagnosed, Combination therapy, Recurrent) in the USA (Intradermal) in August 2021 (NCT04989946)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top